The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Nanoparticle Imaging of Integrins on Tumor Cells
Open accessAbstract
Nanoparticles 10 to 100 nm in size can deliver large payloads to molecular targets, but undergo slow diffusion and/or slow transport through delivery barriers. To examine the feasibility of nanoparticles targeting a marker expressed in tumor cells, we used the binding of cyclic arginine-glycine-aspartic acid (RGD) nanoparticle targeting integrins on BT-20 tumor as a model system. The goals of this study were: 1) to use nanoparticles to image alpha(V)beta3 integrins expressed in BT-20 tumor cells by fluorescence-based imaging and magnetic resonance imaging, and, 2) to identify factors associated with the ability of nanoparticles to target tumor cell integrins. Three factors were identified: 1) tumor cell integrin expression (the alpha(V)beta3 integrin was expressed in BT-20 cells, but not in 9L cells); 2) nanoparticle pharmacokinetics (the cyclic RGD peptide cross-linked iron oxide had a blood half-life of 180 minutes and was able to escape from the vasculature over its long circulation time); and 3) tumor vascularization (the tumor had a dense capillary bed, with distances of <100 microm between capillaries). These results suggest that nanoparticles could be targeted to the cell surface markers expressed in tumor cells, at least in the case wherein the nanoparticles and the tumor model have characteristics similar to those of the BT-20 tumor employed here.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029 · cited 1×
“gov/) [1–3].”
Winter, P. M., Morawski, A. M., Caruthers, S. D., Fuhrhop, R. W., Zhang, H., Williams, T. A., Allen, J. S., Lacy, E. K., Robertson, J. D., Lanza, G. M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000093185.16083.95 · Cited by 696 · cited 1×
“Nanoparticles have been used to image integrins in endothelial cells, particularly the endothelial cells of angiogenic blood vessels [13–19], or to image nonintegrin targets where”
Method
Cited by
Laurent, S., Forge, D., Port, M., Roch, A., Robic, C., Vander Elst, L., & Muller, R. N. (2008) · Chemical Reviews · doi:10.1021/cr068445e · Cited by 6,852
Magnetic nanoparticles in MR imaging and drug delivery
Sun, C., Lee, J. S. H., & Zhang, M. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.018 · Cited by 2,594
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging
Veiseh, O., Gunn, J. W., & Zhang, M. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.002 · Cited by 1,832
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Multimodality Imaging Probes: Design and Challenges
Louie, A. (2010) · Chemical Reviews · doi:10.1021/cr9003538 · Cited by 1,044
Metadata
- Authors
- Montet, X., Montet-Abou, K., Reynolds, F., Weissleder, R., & Josephson, L.
- Venue
- Neoplasia
- Publisher
- Elsevier BV
- Published
- 2006-03
- Volume
- 8
- Issue
- 3
- Pages
- 214-222
- ISSN
- 1476-5586 (ISSN-L)
- OpenAlex
- W2019430054
- Cited by
- 251
- References
- 3
- FWCI
- 11.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.